Cargando…

LGG-29. Use of Bevacizumab in Pediatric Low-grade Glioma: Ten-year experience in a single center

PURPOSE: Pediatric low-grade gliomas (PLGG) have excellent overall survival but frequently need non-surgical therapy at diagnosis or after progression at unresectable sites such as the optic pathway. Chemotherapy side effects have led to the need for better-tolerated regimens with a sustained respon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rafael, Margarida Simão, Cruz, Ofelia, Perez-Jaume, Sara, Santa-María, Vicente, Lavarino, Cinzia, Salvador, Hector, Muchart, Jordi, Hinojosa, Jose, Suñol, Mariona, Morales, Andrés
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Low Grade Glioma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164899/ http://dx.doi.org/10.1093/neuonc/noac079.342

Ejemplares similares

LGG-29. TREATMENT FOR RECURRENT OPTIC PATHWAY PILOCYTIC ASTROCYTOMA
por: Nonaka, Masahiro, et al.
Publicado: (2020)

LGG-42. BEVACIZUMAB-ASSOCIATED SECONDARY AMENORRHEA AND PREMATURE OVARIAN FAILURE IN ADOLESCENT FEMALE PATIENTS WITH LOW-GRADE CNS DISEASE
por: Zhukova, Nataliya, et al.
Publicado: (2020)

LGG-43. Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas
por: Dassi, Natália, et al.
Publicado: (2022)

LGG-11. Analysis of neurosurgical complications in pediatric supratentorial midline low-grade glioma – results from the German LGG studies
por: Weiß, Sarah, et al.
Publicado: (2022)

LGG-09. A Nationwide Service Evaluation of Safety, Radiologic and Visual Outcome Refining Bevacizumab-based Treatments in Children with Progressive Low-Grade Glioma
por: Green, Katherine, et al.
Publicado: (2022)

LGG-11. INSTITUTIONAL EXPERIENCE OF BRAF TARGETING THERAPY
por: Lola, Gino Bardi, et al.
Publicado: (2020)

LGG-18. EVEROLIMUS TREATMENT IN PEDIATRIC PATIENTS AFFECTED BY LOW-GRADE GLIOMAS (pLGG) NON-TSC, BRAF v600-WT
por: Cacchione, Antonella, et al.
Publicado: (2020)

LGG-53. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG)
por: Mueller, Sabine, et al.
Publicado: (2020)

LGG-03. INCIDENCE AND OUTCOME OF PEDIATRIC IDH-MUTANT GLIOMA
por: Yeo, Kee Kiat, et al.
Publicado: (2020)

LGG-32. CLINICAL OUTCOME OF PEDIATRIC GLIOMAS IN SINGLE INSTITUTION
por: Uchida, Hiroyuki, et al.
Publicado: (2020)

LGG-57. SIGNALLING MECHANISMS IN PAEDIATRIC LOW-GRADE GLIOMA
por: Patel, Ankit, et al.
Publicado: (2020)

LGG-49. SAFETY AND EFFICACY OF TRAMETINIB (T) MONOTHERAPY AND DABRAFENIB + TRAMETINIB (D+T) COMBINATION THERAPY IN PEDIATRIC PATIENTS WITH BRAF V600-MUTANT LOW-GRADE GLIOMA (LGG)
por: Bouffet, Eric, et al.
Publicado: (2020)

LGG-46. MOLECULAR CHARACTERIZATION OF HEMISPHERIC LOW-GRADE GLIOMAS IN CHILDREN
por: Mišove, Adéla, et al.
Publicado: (2020)

LGG-13. THE CLINICAL AND MOLECULAR LANDSCAPE OF GLIOMAS IN ADOLESCENTS AND YOUNG ADULTS
por: Bennett, Julie, et al.
Publicado: (2020)

LGG-42. Thromboembolic toxicity observed with concurrent trametinib and lenalidomide therapy
por: Chan, Priya, et al.
Publicado: (2022)

LGG-41. The clinical and molecular landscape of gliomas in adolescents and young adults
por: Bennett, Julie, et al.
Publicado: (2022)

LGG-37. Long-term Outcome, Visual Morbidity and Prognostic Factors in Infants and Young Children with Optic Pathway Glioma from the Great Ormond Street Hospital (GOSH) LGG - Cohort
por: Picariello, Stefania, et al.
Publicado: (2022)

LGG-44. PROGNOSTIC SIGNIFICANCE OF IMAGING CHARACTERISTICS IN PEDIATRIC LOW GRADE GLIOMAS
por: Baig, Muhammad, et al.
Publicado: (2020)

LGG-06. LONG-TERM OUTCOME OF NEWLY DIAGNOSED LOW GRADE GLIOMA
por: Sirachainan, Nongnuch, et al.
Publicado: (2020)

LGG-10. AN UNUSUAL PRESENTATION OF BILATERAL OPTIC NERVE GLIOMA IN CROUZON SYNDROME
por: Na, Brian, et al.
Publicado: (2021)

LGG-02. PEDIATRIC LOW-GRADE GLIOMA RISK STRATIFICATION IN THE MOLECULAR ERA
por: Hata, Jessica, et al.
Publicado: (2021)

LGG-14. MULTI-OMIC ANALYSIS OF MAPK ACTIVATION IN PEDIATRIC PILOCYTIC ASTROCYTOMA
por: Sigaud, Romain, et al.
Publicado: (2020)

LGG-20. CLINICAL FEATURES AND TREATMENT RESULTS FOR PEDIATRIC OPTICO-HYPOTHALAMIC ASTROCYTOMA
por: Yoshimoto, Koji, et al.
Publicado: (2020)

LGG-45. A REPORT OF IDH-MUTANT BRAINSTEM ASTROCYTOMAS IN YOUNG ADULTS
por: Chang, Ellen, et al.
Publicado: (2020)

LGG-04. Clinical and molecular characterization of metastatic pediatric low grade gliomas
por: Lindsay, Holly, et al.
Publicado: (2022)

LGG-59. Identifying hidden drivers of low-grade glioma tumor growth
por: Misek, Sean, et al.
Publicado: (2022)

LGG-03. Pediatric spinal deformities concomitant with spinal cord pilocytic astrocytoma
por: Kapitancuke, Monika, et al.
Publicado: (2022)

LGG-20. Defining subgroups in low grade gliomas by their immune and stromal microenvironment
por: Körner, Meik, et al.
Publicado: (2022)

LGG-61. Cerebrospinal fluid as a source for liquid biopsy in pediatric gliomas
por: Nobre, Liana, et al.
Publicado: (2022)

LGG-36. Analysis of BRAF-related mutations in pediatric low-grade glioma
por: Li, Shaoqun, et al.
Publicado: (2022)

LGG-02. Cardiac toxicity in patients receiving single-agent MEK inhibition
por: Cantor, Evan, et al.
Publicado: (2022)

LGG-04. A PHASE II RE-TREATMENT STUDY OF SELUMETINIB FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (pLGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
por: Fangusaro, Jason, et al.
Publicado: (2020)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

LGG-14. PRESENTATION CHARACTERISTICS AND TREATMENT OUTCOMES FOR PEDIATRIC OPTIC PATHWAY GLIOMAS IN QATAR
por: Maaz, Ata, et al.
Publicado: (2021)

LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS
por: Hanzlik, Emily, et al.
Publicado: (2021)

LGG-13. PILOCYTIC ASTROCYTOMAS WITH NOVEL BRAF FUSIONS DEMONSTRATE MAPK PATHWAY ACTIVATION
por: Chatwin, Hannah, et al.
Publicado: (2021)

LGG-22. EVALUATION OF IMMUNE AND GENOMIC CHARACTERISTICS IN PEDIATRIC OPTIC NERVE GLIOMA (ONG)
por: Campbell, Ashley A, et al.
Publicado: (2020)

LGG-12. TRAMETINIB FOR PEDIATRIC LOW GRADE GLIOMAS: A SINGLE INSTITUTION EXPERIENCE
por: Barbour, Mustafa, et al.
Publicado: (2020)

LGG-27. TARGETED THERAPY FOR PEDIATRIC LOW-GRADE GLIOMAS AND PLEXIFORM NEUROFIBROMAS WITH TRAMETINIB
por: Nguyen, Tiffany, et al.
Publicado: (2020)

LGG-55. Autophagy sensitizes CNS tumors to targeted therapy by lowering their apoptotic threshold
por: Crespo, Michele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oiijk7v0jlupq15sfg29serqq3